CODEXIS, INC.
About CODEXIS, INC.
Codexis, Inc. is a leading enzyme engineering company powering scalable, sustainable solutions for therapeutic development. With its proprietary CodeEvolver® and ECO Synthesis™ platforms, it creates manufacturing solutions for challenges once thought unsolvable, delivering high-performance enzymes for RNAi therapeutics, diagnostics, and small molecule manufacturing. The company is publicly traded on the Nasdaq Global Market under the symbol CDXS and is headquartered in Redwood City, California.
- 🔗 Codexis - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Codexis Prices $25 Million Underwritten Public Offering of Common Stock | Quiver Quantitative
- 🔗 Codexis Announces Proposed Public Offering of Common Stock :: Codexis, Inc. (CDXS)
- 🔗 CDXS Stock Slides As Dilutive Offering Reshapes Trading Setup - StocksToTrade
- 🔗 FAQ :: Codexis, Inc. (CDXS)
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Total funding of $111M across 9 rounds since 2002 with 14 institutional investors.
- Recent $25M underwritten public offering of common stock to fund R&D and operations.
- Publicly traded on NASDAQ under ticker CDXS.
- Employs 193 people as of end of 2024 with revenue between $50M-$100M.
- Focuses on enzymatic solutions for oligonucleotide therapeutics manufacturing.
Tech stack
Ask StreetZero about CODEXIS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account